Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost savings. This commentary discusses CGM implementation and funding policies in the UK, and regional disparities that confront many people with diabetes who could benefit from the technology.
Continuous glucose monitoring,
Nick Oliver has received research
support from Dexcom, Inc. This article is a short
opinion piece and has not been submitted to
external peer reviewers, but was reviewed by the
editorial board for accuracy before publication.
Nick Oliver, Section of
Diabetes, Endocrinology and Metabolism, Faculty of
Medicine, Imperial College, Du Cane Road, London,
W12 0HS, UK. E: Nick.email@example.com
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the author and do not
necessarily reflect those of Dexcom, Inc.
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original.
Share this Article
Related Content In Diabetes
Perspectives on the Barriers and Benefits of Diabetes Technology in Older Adults with Diabetes in the USA
US Endocrinology. 2021;17(1):1–8
The World Health Organization (WHO) defines older adults as people aged 65 years or older.1 Today, older adults with diabetes mellitus (DM) are a growing population, with 33% of older adults meeting the criteria for DM.2 The risk of DM-related complications is elevated in this population; functional decline, comorbid conditions, hypoglycemia and polypharmacy-related adverse events cause significant […]
Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes
touchREVIEWS in Endocrinology. 2021;17(2):92–101 DOI: https://doi.org/10.17925/EE.2021.17.2.92
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycaemia resulting from insulin resistance, inefficient insulin secretion and disproportionate glucagon secretion.1 It has been reported to be an expanding global health issue of the 21st century, and one of the leading causes of morbidity and mortality in Western countries.2,3 Interestingly, an increasing number of publications […]
Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
touchREVIEWS in Endocrinology. 2021;17(2):84–7 DOI: https://doi.org/10.17925/EE.2021.17.2.84
Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1 Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results in a high incidence of diabetic kidney disease (DKD), which, together with hypertension, is the main […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!